Stocktoria
Liquidia Corp LQDA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-07-26
Liquidia Corp financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $158.3M | $14.0M | $17.5M | $15.9M | $12.9M | $739,628 | $8.1M |
| R&D expense | $39.3M | $47.8M | $43.2M | $19.4M | $20.5M | $32.2M | $40.5M |
| SG&A expense | $157.2M | $81.6M | $44.7M | — | — | — | — |
| Operating income | -$51.4M | -$121.3M | -$73.4M | -$38.8M | -$33.8M | -$59.1M | -$46.8M |
| Interest expense | — | — | $6.3M | $2.3M | $762,000 | $857,998 | $1.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$68.9M | -$128.3M | -$78.5M | -$41.0M | -$34.6M | -$59.8M | -$47.6M |
| EPS (diluted) | $-0.80 | $-1.63 | $-1.21 | $-0.67 | $-0.70 | $-1.76 | $-2.57 |
| Operating cash flow | -$35.7M | -$93.4M | -$41.6M | -$28.6M | -$34.0M | -$54.1M | -$48.3M |
| Free cash flow | -$40.0M | -$98.4M | -$42.9M | -$29.2M | -$34.1M | -$54.9M | -$50.1M |
| Cash & equivalents | $190.7M | $176.5M | $83.7M | $93.3M | $57.5M | $65.3M | — |
| Inventory | $23.8M | $241,000 | — | — | — | — | — |
| Total assets | $327.9M | $230.3M | $118.3M | $129.2M | $93.7M | $99.5M | $68.8M |
| Total liabilities | $283.2M | $150.9M | $71.0M | $38.8M | $28.5M | $28.4M | $33.9M |
| Shareholders' equity | $44.7M | $79.4M | $47.3M | $90.4M | $65.3M | $71.1M | $34.9M |
Growth · year-over-year · Revenue CAGR 64.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +1031.2% | -20.0% | +9.7% | +24.0% | +1637.8% | -90.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.